Overview

* Protara reports Q3 net loss of $13.3 mln, increased from $11.2 mln in 2024

* Company anticipates key clinical milestones in late 2025 and early 2026

Outlook

* Protara expects interim results from NMIBC trial in 1Q 2026

* Company plans to initiate dosing in THRIVE-3 trial by year-end 2025

* Protara expects cash reserves of $134 mln to support operations into mid-2027

Result Drivers

* CLINICAL TRIAL PROGRESS - Protara continues to advance its clinical programs with significant milestones expected in late 2025 and early 2026, including interim analyses for TARA-002 in NMIBC and LMs

* THRIVE-3 TRIAL - Dosing in the THRIVE-3 trial for IV Choline Chloride is expected to begin by year-end 2025, addressing administrative and funding challenges

* CASH POSITION - Protara's cash reserves of $134 mln are expected to support operations into mid-2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.31

Q3 Net -$13.26

Income mln

Q3 -$14.76

Income mln

from

Operatio

ns

Q3 $14.76

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Protara Therapeutics Inc ( TARA ) is $24.50, about 82.5% above its November 7 closing price of $4.29

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)